Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

Elizabeth Plimack, MD
Published: Wednesday, Nov 29, 2017



Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

There are currently 2 approved checkpoint inhibitors for the first-line treatment of patients with metastatic bladder cancer who are cisplatin ineligible—pembrolizumab (Keytruda) and atezolizumab (Tecentriq).

The results with either of these agents can be durable in this patient population, says Plimack, but there is currently no long-term follow-up data available.
 


Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

There are currently 2 approved checkpoint inhibitors for the first-line treatment of patients with metastatic bladder cancer who are cisplatin ineligible—pembrolizumab (Keytruda) and atezolizumab (Tecentriq).

The results with either of these agents can be durable in this patient population, says Plimack, but there is currently no long-term follow-up data available.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x